The Effectiveness of an Innovative Inhalation Training Device in Improving Medication Accuracy, Dyspnea, and Quality of Life in Elderly Patients With Chronic Obstructive Pulmonary Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Innovative Inhaler Training Device (金犀利), Standard pMDI Inhaler Education.
- Who it may be relevant to
- Registry conditions: Chronic Obstructive Pulmonary Disease. Basic parameters: from 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Taiwan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to evaluate the effectiveness of an innovative inhaler training device, "Golden Rhino" (pMDI Practice Tool), in improving inhalation technique accuracy, dyspnea severity, and quality of life among elderly patients with chronic obstructive pulmonary disease (COPD). The device integrates a weighted valve and musical cues to guide patients in synchronizing their breath with proper pMDI inhalation technique. Participants will be randomly assigned to either standard nursing guidance or nursing guidance plus device-based training. Outcome measures include pMDI usage accuracy, dyspnea severity, and EQ-5D quality of life scores at baseline and follow-up.
Detailed description
Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity among older adults. Effective pMDI inhalation technique is critical for symptom control, yet improper use is common among elderly patients, especially those with cognitive decline or low health literacy. To address this, we developed an innovative training tool, "Golden Rhino" (patent number M647974, Taiwan), which utilizes a weight-calculated valve to simulate proper inhalation flow (20-60 L/min) and incorporates music cues to assist in breath timing (inhale, hold, exhale).
This randomized controlled trial investigates whether adding this tool to routine nursing education improves pMDI technique accuracy, alleviates dyspnea (via mMRC and CAT), and enhances quality of life (via EQ-5D-5L) in elderly COPD patients. Eligible participants aged 65 years and above will be enrolled from a medical center. Intervention group patients will use the device under nursing instruction for one week. The control group will receive standard verbal instructions only. Assessments occur at baseline, one week, and one month post-intervention.
The device is a non-commercial, research-use-only prototype with no financial gain or commercialization involved. This study has disclosed all relevant intellectual property in the IRB process and participant consent forms.
Interventions
- Behavioral Innovative Inhaler Training Device (金犀利)
This intervention involves the use of an innovative inhaler training device designed to assist elderly COPD patients in mastering the correct pMDI inhalation technique. The device provides visual and auditory feedback during training and is used in conjunction with individualized nursing instruction. The goal is to improve medication administration accuracy, reduce dyspnea, and enhance quality of life. - Behavioral Standard pMDI Inhaler Education
Participants receive standard pMDI inhaler education only, based on established clinical nursing guidelines. No additional device or interactive training is provided. The education includes written and verbal instructions on proper pMDI use.
Primary outcome measures
- Change in dyspnea severity [Time frame: Pre-intervention, immediately post-intervention, 4 weeks, 12 weeks]
- Correct use of pMDI inhaler [Time frame: Pre-intervention, immediately post-intervention, 4 weeks, 12 weeks]
- Health-related quality of life (HRQoL) [Time frame: Pre-intervention, immediately post-intervention, 4 weeks, 12 weeks]
Secondary outcome measures (3)
- Change in peak expiratory flow (PEF) [Time frame: Pre-intervention, immediately post-intervention, 4 weeks, 12 weeks]
- Change in forced expiratory volume in one second (FEV₁) [Time frame: Pre-intervention, immediately post-intervention, 4 weeks, 12 weeks]
- Change in COPD Assessment Test (CAT) score [Time frame: Pre-intervention, immediately post-intervention, 4 weeks, 12 weeks]
Eligibility criteria
Inclusion criteria
- Age ≥ 65 years old
- Clinically diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD criteria
- Currently using pressurized Metered Dose Inhaler (pMDI) medications
- Ability to communicate and understand instructions in Mandarin or Taiwanese
- Willing to participate and provide informed consent
Exclusion criteria
- Diagnosis of severe cognitive impairment (e.g., dementia) that may interfere with participation
- Acute COPD exacerbation requiring hospitalization within the past 30 days
- Concurrent enrollment in another interventional clinical trial
- Severe visual or hearing impairment that may limit the ability to follow inhaler training instructions
- Other diagnosed pulmonary diseases (e.g., lung cancer, pulmonary fibrosis) that may affect the assessment of COPD outcomes
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Health services research
Study locations
Taiwan · 1 center
- Taipei Veterans General Hospital — Taipei
Identifiers
NCT: NCT07305649 · 2025-06-003B